References
The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med. 1999;341(8):556-562.
. HCV-positive allograft use in heart transplantation is associated with increased access to overdose donors and reduced waitlist mortality without compromising outcomes. J Card Fail. 2022;28(1):32-41. doi:10.1016/j.cardfail.2021.07.007.
. Zidovudine use but not weight-based ribavirin dosing impacts anaemia during HCV treatment in HIV-infected persons. J Viral Hepat. 2006;13:683-689.
. .; 2010.
Prevalence of hepatitis C virus infection among injection drug users in the United States, 1994-2004. Clin Infect Dis. 2008;46(12):1852-1858.
ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b infection. Gastroenterology. 2014;147(2):359-365.
Anti-HCV testing as a basic standard of monitoring HCV mother-to-child infection: advantages and disadvantages of the method. Przegl Epidemiol. 2012;66:341-345.
. Investigation of pharmacokinetic interactions between doravirine and elbasvir-grazoprevir and ledipasvir-sofosbuvir. Antimicrob Agents Chemother. 2019;63(5):e02491-18.
. Risk factors for HCV acquisition among HIV-positive MSM in Belgium. J Acquir Immune Defic Syndr. 2015;68(5):585-593.
Outcomes following liver transplantation from HCV-seropositive donors to HCV-seronegative recipients. J Hepatol. 2021;74(4):873-880.
. A prospective study of hepatitis C virus infection after needlestick accidents. Liver. 1996;16(5):331-334.
Sustained virological response reduces incidence of onset of type 2 diabetes in chronic hepatitis C. Hepatology. 2009;49(3):739-744.
Distinguishing acute from chronic hepatitis C virus (HCV) infection based on antibody reactivities to specific HCV structural and nonstructural proteins. J Clin Microbiol. 2011;49(1):54-57.
. Mobile technology to increase HIV/HCV testing and overdose prevention/response among people who inject drugs. Front Public Health. 2017;5:217.
. Outcomes of treatment for hepatitis C virus infection by primary care providers. N Engl J Med. 2011;364(23):2199-2207.
Patterns of drug and alcohol use and injection equipment sharing among people with recent injection drug use or receiving opioid agonist treatment during and following hepatitis C virus treatment with direct-acting antiviral therapies [truncated]. Clin Infect Dis. 2020;70(11):2369-2376.
. Treatment of hepatitis C virus infection among people who are actively injecting drugs: a systematic review and meta-analysis. Clin Infect Dis. 2013;57(Suppl 2):S80-S89.
Efficacy of glecaprevir/pibrentasvir for 8 or 12 weeks in patients with hepatitis C virus genotype 2, 4, 5, or 6 infection without cirrhosis. Clin Gastroenterol Hepatol. 2018;16(3):417-426.
Efficacy of elbasvir and grazoprevir in participants with hepatitis C virus genotype 4 infection: a pooled analysis. Liver Int. 2018;38(9):1583-1591.
. Sofosbuvir/velpatasvir in patients with hepatitis C virus genotypes 1-6 and compensated cirrhosis or advanced fibrosis. Liver Int. 2018;38(3):443-450.